Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, placebo-controlled Phase 2 study of MIN-102 in Friedreich's ataxia
2018-004405-64Phase 2Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing MIN-102 with Placebo (2 arms). Primary endpoint: Change from baseline in spinal cord area cervical segment C2-C3. Started Dec 2018; status: completed.
02
Drugs
leriglitazone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2018-004405-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004405-64.